A Study to Evaluate Alloantibody Titer in Highly Sensitized Kidney Transplant Candidates

Overview

  • Study type

    Observational
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • Site IRB
    • Jacksonville, Florida: 19-003562
    • Rochester, Minnesota: 19-003562
    • Scottsdale/Phoenix, Arizona: 19-003562
    Sponsor Protocol Number: 19-003562

About this study

The purpose of this study is to evaluate the utility of using anti-HLA antibody titer to measure the effectiveness of antibody lowering therapy (i.e., desensitization) in highly-sensitized kidney transplant candidates.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

  • Kidney and/or pancreas transplant candidates with calculated panel reactive antibodies > 99% (this is a measure of sensitization, not age).

Exclusion Criteria: 

  • Receipt of a blood transfusion, transplant, or transplant nephrectomy within the 6-9 month follow-up between sample collection.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Contact us for the latest status

Contact information:

Katelyn Register

127or7838503

Register.Katelyn@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Contact us for the latest status

Contact information:

Mark Stegall M.D.

Stegall.Mark@mayo.edu

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Contact us for the latest status

Contact information:

Raymond Heilman M.D.

(480)342-0161

heilman.raymond@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20467360

Mayo Clinic Footer